中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2015年
12期
83-85,120
,共4页
胰岛素强化治疗%糖尿病肾病%色素上皮衍生因子%血管内皮生长因子
胰島素彊化治療%糖尿病腎病%色素上皮衍生因子%血管內皮生長因子
이도소강화치료%당뇨병신병%색소상피연생인자%혈관내피생장인자
Intensive insulin therapy%Diabetic nephropathy%PEDF%VEGF
目的:观察不同时期糖尿病肾病患者血清色素上皮衍生因子(PEDF)、血管内皮生长因子(VEGF)水平的差异,并探讨胰岛素强化治疗对其血清PEDF及VEGF水平的影响。方法选取2012年12月~2013年12月在北京军区总医院住院的2型糖尿病患者(符合1999年WHO糖尿病诊断标准)85例,根据尿白蛋白/肌酐比值(UACR)分为三组院正常白蛋白尿组(A组)30例(UACR约30 mg/g);微量白蛋白尿组(B组)28例(30 mg/g≤UACR约300 mg/g);大量白蛋白尿组(C组)27例(UACR≥300 mg/g)。分别给予14 d的胰岛素强化治疗,于治疗前后测定空腹血糖(FPG)、餐后2 h血糖(2hPBG)、糖化血清蛋白(GSP)、PEDF、VEGF、UACR,并对各指标进行分析。结果①治疗前B、C组PEDF、VEGF明显高于A组(P<0.01),且C组明显高于B组(P<0.01)。②胰岛素强化治疗后,三组FPG、2hPBG、GSP、PEDF和VEGF均较治疗前明显下降(P<0.05或P<0.01)。结论①糖尿病肾病患者的PEDF、VEGF水平明显高于正常蛋白尿的糖尿病患者,随着白蛋白尿的增加,PEDF、VEGF水平明显升高。②无论是否合并糖尿病肾病,胰岛素强化治疗均可以在降血糖的同时,改善其PEDF、VEGF水平。
目的:觀察不同時期糖尿病腎病患者血清色素上皮衍生因子(PEDF)、血管內皮生長因子(VEGF)水平的差異,併探討胰島素彊化治療對其血清PEDF及VEGF水平的影響。方法選取2012年12月~2013年12月在北京軍區總醫院住院的2型糖尿病患者(符閤1999年WHO糖尿病診斷標準)85例,根據尿白蛋白/肌酐比值(UACR)分為三組院正常白蛋白尿組(A組)30例(UACR約30 mg/g);微量白蛋白尿組(B組)28例(30 mg/g≤UACR約300 mg/g);大量白蛋白尿組(C組)27例(UACR≥300 mg/g)。分彆給予14 d的胰島素彊化治療,于治療前後測定空腹血糖(FPG)、餐後2 h血糖(2hPBG)、糖化血清蛋白(GSP)、PEDF、VEGF、UACR,併對各指標進行分析。結果①治療前B、C組PEDF、VEGF明顯高于A組(P<0.01),且C組明顯高于B組(P<0.01)。②胰島素彊化治療後,三組FPG、2hPBG、GSP、PEDF和VEGF均較治療前明顯下降(P<0.05或P<0.01)。結論①糖尿病腎病患者的PEDF、VEGF水平明顯高于正常蛋白尿的糖尿病患者,隨著白蛋白尿的增加,PEDF、VEGF水平明顯升高。②無論是否閤併糖尿病腎病,胰島素彊化治療均可以在降血糖的同時,改善其PEDF、VEGF水平。
목적:관찰불동시기당뇨병신병환자혈청색소상피연생인자(PEDF)、혈관내피생장인자(VEGF)수평적차이,병탐토이도소강화치료대기혈청PEDF급VEGF수평적영향。방법선취2012년12월~2013년12월재북경군구총의원주원적2형당뇨병환자(부합1999년WHO당뇨병진단표준)85례,근거뇨백단백/기항비치(UACR)분위삼조원정상백단백뇨조(A조)30례(UACR약30 mg/g);미량백단백뇨조(B조)28례(30 mg/g≤UACR약300 mg/g);대량백단백뇨조(C조)27례(UACR≥300 mg/g)。분별급여14 d적이도소강화치료,우치료전후측정공복혈당(FPG)、찬후2 h혈당(2hPBG)、당화혈청단백(GSP)、PEDF、VEGF、UACR,병대각지표진행분석。결과①치료전B、C조PEDF、VEGF명현고우A조(P<0.01),차C조명현고우B조(P<0.01)。②이도소강화치료후,삼조FPG、2hPBG、GSP、PEDF화VEGF균교치료전명현하강(P<0.05혹P<0.01)。결론①당뇨병신병환자적PEDF、VEGF수평명현고우정상단백뇨적당뇨병환자,수착백단백뇨적증가,PEDF、VEGF수평명현승고。②무론시부합병당뇨병신병,이도소강화치료균가이재강혈당적동시,개선기PEDF、VEGF수평。
Objective To observe the differences of serum pigment epithelium derived factor (PEDF), vascular endothe-lial growth factor (VEGF) levels of patients with diabetic nephropathy in different periods and to explore the impact of intensive insulin therapy on patients' levels of serum PEDF, VEGF. Methods 85 cases of type 2 diabetes inpatients (comply with the 1999 WHO diagnostic criteria for diabetes) treated in the Department of Endocrinology of Beijing Military General Hospital from December 2012 to December 2013 were selected, and the subjects were divided into three groups according to the urine albumin creatinine ratio (UACR):30 cases with normal albuminuria (UACR<30 mg/g) in group A;28 cases with light albuminuria (30 mg/g≤UACR<300 mg/g) in group B and 27 cases with macroalbumin-uria (UACR≥300 mg/g) in group C. The subjects in each group were given 14-days treatment of intensive insulin therapy. FPG, 2hPBG, GSP, PEDF, VEGF, UACR before and after treatment were measured and each indicator was analyzed. Results①The levels of PEDF, VEGF before treatment in group B and C were higher than those of group A (P< 0.01), and group C was obviously higher than group B (P<0.01).②FPG, 2hPBG, GSP, PEDF, VEGF were obviously declined after intensive insulin treatment in three groups (P<0.05 or P<0.01). Conclusion①PEDF, VEGF levels of diabetic nephropathy are significantly higher than those with normal albuminuria, and with the increase in albuminuria, PEDF, VEGF levels increase significantly. ②Whether diabetes combines with nephropathy or not, intensive insulin therapy can improve the PEDF and VEGF levels while lowering blood glucose.